A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Phase of Trial: Phase II/III
Latest Information Update: 20 Apr 2017
Price : $35 *
At a glance
- Drugs Riluzole (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 17 Apr 2017 Status changed from recruiting to completed.
- 31 Aug 2016 Planned End Date changed from 1 Jul 2015 to 1 Jul 2017.
- 27 Apr 2014 New trial record